Article Contents
ARTICLE   Open Access     Cite

Lipid droplets control anti-tumor immunity by depleting Golgi DAG and blocking IFNGR1 surface trafficking

More Information
  • DownLoad: Full size image
    1. Tumor LDs suppress IFNGR1 surface trafficking to drive anti-PD-1 resistance.

      FITM2-driven LD biogenesis preferentially depletes TGN diacylglycerol to impair IFNGR1 trafficking.

      DGAT1 inhibition restores IFNGR1 trafficking and sensitizes CRC to anti-PD-1.

      LDs are organelles that control cytokine receptor trafficking and anti-tumor immunity.

  • Resistance to anti-PD-1 therapy remains a major challenge in colorectal cancer (CRC), particularly in microsatellite-stable tumors, yet the underlying mechanisms are incompletely understood. Here, we identify tumor lipid droplets (LDs) as a driver of immune evasion and anti-PD-1 resistance. In CRC patients receiving anti-PD-1 therapy, progressive disease correlates with high tumor LD content and reduced plasma membrane IFNGR1. Mechanistically, fat storage-inducing transmembrane protein 2 (FITM2)-driven LD biogenesis preferentially depletes trans-Golgi network (TGN) diacylglycerol (DAG) without altering total cellular DAG or other TGN lipids, thereby impairing IFNGR1 vesicular trafficking to the plasma membrane and attenuating JAK2-STAT1 signaling. Genetic (FITM2 knockdown) or pharmacological (DGAT1 inhibitor A922500) LD reduction restores TGN DAG pools, rescues IFNGR1 surface localization, reactivates IFN-γ signaling, and synergizes with anti-PD-1 therapy in orthotopic CRC models. These findings define LD-driven TGN DAG depletion as a mechanistic link between lipid metabolism and immunotherapy resistance and nominate LD biogenesis targeting as a strategy to overcome anti-PD-1 resistance.
  • 加载中
  • [1] Dekker E., Tanis P.J., Vleugels J.L.A., et al. (2019). Colorectal cancer. Lancet 394:1467−1480. DOI:10.1016/S0140-6736(19)32319-0

    View in Article CrossRef Google Scholar

    [2] Apriamashvili G., Vredevoogd D.W., Krijgsman O., et al. (2022). Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNgamma signaling. Nat. Commun. 13:1923. DOI:10.1038/s41467-022-29442-x

    View in Article CrossRef Google Scholar

    [3] Lizardo D.Y., Kuang C., Hao S., et al. (2020). Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim. Biophys. Acta Rev. Cancer 1874:188447. DOI:10.1016/j.bbcan.2020.188447

    View in Article CrossRef Google Scholar

    [4] Pecci F., Cantini L., Bittoni A., et al. (2021). Beyond microsatellite instability: Evolving strategies integrating immunotherapy for microsatellite stable colorectal cancer. Curr. Treat. Options Oncol. 22:69. DOI:10.1007/s11864-021-00870-z

    View in Article CrossRef Google Scholar

    [5] Baraibar I., Mirallas O., Saoudi N., et al. (2021). Combined treatment with immunotherapy-based strategies for MSS metastatic colorectal cancer. Cancers (Basel) 13:6311. DOI:10.3390/cancers13246311

    View in Article CrossRef Google Scholar

    [6] Ganesh K., Stadler Z.K., Cercek A., et al. (2019). Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16:361−375. DOI:10.1038/s41575-019-0126-x

    View in Article CrossRef Google Scholar

    [7] Wang C. and Fakih M. (2021). Targeting MSS colorectal cancer with immunotherapy: Are we turning the corner. Expert Opin. Biol. Ther. 21:1347−1357. DOI:10.1080 /14712598. 2021.1 933940.

    View in Article Google Scholar

    [8] Schoenfeld A.J. and Hellmann M.D. (2020). Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37:443−455. DOI:10.1016/j.ccell.2020.03.017

    View in Article CrossRef Google Scholar

    [9] Bagchi S., Yuan R. and Engleman E.G. (2021). Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16:223−249. DOI:10.1146/annurev-pathol-042020-042741

    View in Article CrossRef Google Scholar

    [10] Kim T.K., Vandsemb E.N., Herbst R.S., et al. (2022). Adaptive immune resistance at the tumour site: Mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21:529−540. DOI:10.1038/s41573-022-00493-5

    View in Article CrossRef Google Scholar

    [11] Kalbasi A. and Ribas A. (2020). Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20:25−39. DOI:10.1038/s41577-019-0218-4

    View in Article CrossRef Google Scholar

    [12] Olzmann J.A. and Carvalho P. (2019). Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 20:137−155. DOI:10.1038/s41580-018-0085-z

    View in Article CrossRef Google Scholar

    [13] Li Z., Liu H. and Luo X. (2020). Lipid droplet and its implication in cancer progression. Am. J. Cancer Res 10:4112−4122.

    View in Article Google Scholar

    [14] Cotte A.K., Aires V., Fredon M., et al. (2018). Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat. Commun. 9:322. DOI:10.1038/s41467-017-02732-5

    View in Article CrossRef Google Scholar

    [15] Kasashima H., Duran A., Cid-Diaz T., et al. (2021). Mouse model of colorectal cancer: Orthotopic co-implantation of tumor and stroma cells in cecum and rectum. STAR Protoc. 2:100297. DOI:10.1016/j.xpro.2021.100297

    View in Article CrossRef Google Scholar

    [16] Campion C.G., Zaoui K., Verissimo T., et al. (2018). COMMD5/HCaRG Hooks endosomes on cytoskeleton and coordinates EGFR trafficking. Cell Rep. 24:670−684e677. DOI:10.1016/j.celrep.2018.06.056

    View in Article CrossRef Google Scholar

    [17] Wei B., Xu L., Guo W., et al. (2021). SHP2-mediated inhibition of DNA repair contributes to cGAS-STING activation and chemotherapeutic sensitivity in colon cancer. Cancer Res. 81:3215−3228. DOI:10.1158/0008-5472.CAN-20-3738

    View in Article CrossRef Google Scholar

    [18] Hu J., Liu W., Zou Y., et al. (2024). Allosterically activating SHP2 by oleanolic acid inhibits STAT3-Th17 axis for ameliorating colitis. Acta Pharm. Sin. B 14:2598−2612. DOI:10.1016/j.apsb.2024.03.017

    View in Article CrossRef Google Scholar

    [19] Bacci M., Lorito N., Smiriglia A., et al. (2024). Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER(+) breast cancer. Sci. Transl. Med. 16:eadf9874. DOI:10.1126/scitranslmed.adf9874

    View in Article CrossRef Google Scholar

    [20] Liu R., Lee J.H., Li J., et al. (2021). Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of lipid droplets. Mol. Cell 81:2722-2735.e9. DOI:10.1016/j.molcel.2021.05.005

    View in Article Google Scholar

    [21] Bosch M., Sanchez-Alvarez M., Fajardo A., et al. (2020). Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense. Science 370:eaay8085. DOI:10.1126/science.aay8085

    View in Article CrossRef Google Scholar

    [22] Lyu X., Wang J., Wang J., et al. (2021). A gel-like condensation of Cidec generates lipid-permeable plates for lipid droplet fusion. Dev. Cell 56:2592-2606.e7. DOI:10.1016/j.devcel.2021.08.015.

    View in Article Google Scholar

    [23] Kadereit B., Kumar P., Wang W.J., et al. (2008). Evolutionarily conserved gene family important for fat storage. Proc. Natl. Acad. Sci. USA 105:94−99. DOI:10.1073/pnas.0708579105

    View in Article CrossRef Google Scholar

    [24] Cheng X., Geng F., Pan M., et al. (2020). Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress. Cell Metab. 32:229−242.e8. DOI:10.1016/j.cmet.2020.06.002

    View in Article CrossRef Google Scholar

    [25] Zhou L., Song Z., Hu J., et al. (2021). ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics 11:841−860. DOI:10.7150/thno.49384

    View in Article CrossRef Google Scholar

    [26] Gao M., Huang X., Song B.L., et al. (2019). The biogenesis of lipid droplets: Lipids take center stage. Prog Lipid Res. 75:100989. DOI:10.1016/j.plipres.2019.100989

    View in Article CrossRef Google Scholar

    [27] Zaidi M.R. and Merlino G. (2011). The two faces of interferon-γ in cancer. Clin. Cancer Res. 17:6118−6124. DOI:10.1158/1078-0432.CCR-11-0482

    View in Article CrossRef Google Scholar

    [28] Londino J.D., Gulick D.L., Lear T.B., et al. (2017). Post-translational modification of the interferon-gamma receptor alters its stability and signaling. Biochem. J. 474:3543−3557. DOI:10.1042/BCJ20170548

    View in Article CrossRef Google Scholar

    [29] Krahmer N., Najafi B., Schueder F., et al. (2018). Organellar proteomics and phospho-proteomics reveal subcellular reorganization in diet-induced hepatic steatosis. Dev. Cell 47:205-221.e7. DOI:10.1016/j.devcel.2018.09.017.

    View in Article Google Scholar

    [30] Xu M., Chen Z.Y., Li Y., et al. (2024). Rab2A-mediated Golgi-lipid droplet interactions support very-low-density lipoprotein secretion in hepatocytes. EMBO J 43:6383−6409. DOI:10.1038/s44318-024-00288-x

    View in Article CrossRef Google Scholar

    [31] Gu F., Crump C.M. and Thomas G. (2001). Trans-Golgi network sorting. Cell Mol. Life Sci. 58:1067−1084. DOI:10.1007/PL00000922

    View in Article CrossRef Google Scholar

    [32] Litvak V., Dahan N., Ramachandran S., et al. (2005). Maintenance of the diacylglycerol level in the Golgi apparatus by the Nir2 protein is critical for Golgi secretory function. Nat. Cell. Biol. 7:225−234. DOI:10.1038/ncb1221

    View in Article CrossRef Google Scholar

    [33] Corbet C., Bastien E., Santiago de Jesus J.P., et al. (2020). TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun. 11:454. DOI:10.1038/s41467-019-14262-3

    View in Article CrossRef Google Scholar

    [34] Wright H.J., Hou J., Xu B., et al. (2017). CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc. Natl. Acad. Sci. USA 114:E6556−E6565. DOI:10.1073/pnas.1703791114

    View in Article CrossRef Google Scholar

    [35] Luis G., Godfroid A., Nishiumi S., et al. (2021). Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and fatty acid biding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox. Biol. 43:102006. DOI:10.1016/j.redox.2021.102006

    View in Article CrossRef Google Scholar

    [36] Accioly M.T., Pacheco P., Maya-Monteiro C.M., et al. (2008). Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res. 68:1732−1740. DOI:10.1158/0008-5472.CAN-07-1999

    View in Article CrossRef Google Scholar

    [37] Zheng M., Zhang W., Chen X., et al. (2023). The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy. Acta Pharm. Sin. B 13:1488−1497. DOI:10.1016/j.apsb.2022.10.027

    View in Article CrossRef Google Scholar

    [38] Niu Z., Chen G., Chang W., et al. (2021). Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity. J. Pathol. 253:247−257. DOI:10.1002/path.5585

    View in Article CrossRef Google Scholar

    [39] Siddiqui S. and Glauben R. (2022). Fatty acid metabolism in myeloid-derived suppressor cells and tumor-associated macrophages: Key factor in cancer immune evasion. Cancers (Basel) 14:250. DOI:10.3390/cancers14010250

    View in Article CrossRef Google Scholar

    [40] Ayers M., Lunceford J., Nebozhyn M., et al. (2017). IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127:2930−2940. DOI:10.1172/JCI91190

    View in Article CrossRef Google Scholar

    [41] Zaretsky J.M., Garcia-Diaz A., Shin D.S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:819−829. DOI:10.1056/NEJMoa1604958

    View in Article CrossRef Google Scholar

    [42] Shin D.S., Zaretsky J.M., Escuin-Ordinas H., et al. (2017). Primary resistance to PD-1 Blockade mediated by JAK1/2 mutations. Cancer Discov. 7:188−201. DOI:10.1158/2159-8290.CD-16-1223

    View in Article CrossRef Google Scholar

    [43] Gao J., Shi L.Z., Zhao H., et al. (2016). Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397−404.e9. DOI:10.1016/j.cell.2016.08.069

    View in Article CrossRef Google Scholar

    [44] Manguso R.T., Pope H.W., Zimmer M.D., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547:413−418. DOI:10.1038/nature23270

    View in Article CrossRef Google Scholar

    [45] Ishizuka J.J., Manguso R.T., Cheruiyot C.K., et al. (2019). Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565:43−48. DOI:10.1038/s41586-018-0768-9

    View in Article CrossRef Google Scholar

    [46] Larson R.C., Kann M.C., Bailey S.R., et al. (2022). CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature 604:563−570. DOI:10.1038/s41586-022-04585-5

    View in Article CrossRef Google Scholar

    [47] Lv C., Yuan D. and Cao Y. (2021). Downregulation of interferon-gamma receptor expression endows resistance to anti-programmed death protein 1 therapy in colorectal cancer. J. Pharmacol. Exp. Ther. 376:21−28. DOI:10.1124/jpet.120.000284

    View in Article CrossRef Google Scholar

    [48] Du W., Hua F., Li X., et al. (2021). Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation. Cancer Discov. 11:1826−1843. DOI:10.1158/2159-8290.CD-20-1571

    View in Article CrossRef Google Scholar

    [49] Krug J., Rodrian G., Petter K., et al. (2023). N-glycosylation regulates intrinsic IFN-γ resistance in colorectal cancer: Implications for immunotherapy. Gastroenterology 164:392-406.e5. DOI:10.1053/j.gastro.2022.11.018

    View in Article Google Scholar

    [50] Soula M., Unlu G., Welch R., et al. (2024). Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. Nature 633:451−458. DOI:10.1038/s41586-024-07787-1

    View in Article CrossRef Google Scholar

    [51] Pestka S., Kotenko S.V., Muthukumaran G., et al. (1997). The interferon gamma (IFN-gamma) receptor: A paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev. 8:189−206. DOI:10.1016/s1359-6101(97)00009-9

    View in Article CrossRef Google Scholar

    [52] Deng B., Kong W., Shen X., et al. (2024). The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications. J. Transl. Med. 22:290. DOI:10.1186/s12967-024-05084-z

    View in Article CrossRef Google Scholar

    [53] Dierge E., Debock E., Guilbaud C., et al. (2021). Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 33:1701-1715.e5. DOI:10.1016/j.cmet.2021.05.016

    View in Article Google Scholar

    [54] Wang L.S., Xu S.W., Zhou M.Z., et al. (2024). The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: A comprehensive review. Int. J. Biol. Macromol. 278:134835. DOI:10.1016/j.ijbiomac.2024.134835

    View in Article Google Scholar

  • Cite this article:

    Xu L., Li Y., Li X., et al. (2026). Lipid droplets control anti-tumor immunity by depleting Golgi DAG and blocking IFNGR1 surface trafficking. The Innovation Oncology 1:100041. https://doi.org/10.59717/j.xinn-oncol.2026.100041
    Xu L., Li Y., Li X., et al. (2026). Lipid droplets control anti-tumor immunity by depleting Golgi DAG and blocking IFNGR1 surface trafficking. The Innovation Oncology 1:100041. https://doi.org/10.59717/j.xinn-oncol.2026.100041

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

Figures(7)    

Supplementary Information

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(538) PDF downloads(156)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint